Reaserch Advances in the Treatment of Primary Immune Thrombocytopenia--Review / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 983-987, 2021.
Article
de Zh
| WPRIM
| ID: wpr-880179
Bibliothèque responsable:
WPRO
ABSTRACT
Primary immune thrombocytopenia (ITP) is a blood system disease mediated by autoimmune mechanism. Currently, the goal of treatment for primary ITP is to keep patients' peripheral platelet count at a safe level to prevent severe bleeding. Recently, avatrombopag and fostamatinib have been approved by the FDA for the treatment of primary ITP in adults, while new drugs such as rozanolixizumab, efgartigimod, PRTX-100, decitabine and atorvastatin have shown efficacy in early clinical trials. This review summarizes the current accepted therapies for the clinical treatment of primary ITP in adults, and briefly discuss the progress of new therapies.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Numération des plaquettes
/
Splénectomie
/
Purpura thrombopénique idiopathique
/
Hémorragie
Limites du sujet:
Adult
/
Humans
langue:
Zh
Texte intégral:
Journal of Experimental Hematology
Année:
2021
Type:
Article